Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3065783 | Journal of Neuroimmunology | 2007 | 6 Pages |
Abstract
IntroductionT cells occupy a central role in MS and CIDP pathogenesis. High dose cyclophosphamide's in-vivo cytotoxic-effect on circulating memory and naïve T cells is unknown.MethodThree MS and five CIDP patients received cyclophosphamide (200 mg/kg) for refractory disease. Before and after chemotherapy administration, peripheral blood T-cell subsets were determined. Patients underwent serial neurologic evaluations quarterly.ResultsCyclophosphamide uniformly decreased clinical disease activity. Compared to memory T cells, naïve T cells were preferentially eradicated.DiscussionCyclophosphamide effectiveness in autoimmune illness may result from Naïve T-cell destruction, as this compartment may be the source of autoreactive lymphocytes.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Douglas E. Gladstone, Marc G. Golightly, Thomas H. Brannagan III,